MedTrace Logo

Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer

NCT06180733 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-05-01

No results posted yet for this study

Summary

The goal of this clinical trial is to establish the fraction of patients that achieve a major pathological response (MPR) after 9 cycles of pembrolizumab, with the ultimate aim of informing a follow-up randomized trial.

Participants will receive 9 cycles of pembrolizumab before their standard of care hysterectomy.

Conditions

Interventions

DRUG

Pembrolizumab Injection [Keytruda]

Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 9 administrations per patient, prior to standard-of-care surgery. Patients will be monitored for response and possible progression using MRI and pipelle biopsies.

Sponsors & Collaborators

Principal Investigators

  • Hans W Nijman, Prof. dr. · University Medical Center Groningen, UMCG

  • Mathilde Jalving, Dr. · University Medical Center Groningen, UMCG

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2027-12-30
Completion
2028-01-31
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06180733 on ClinicalTrials.gov